

NOW ENROLLING

Have You Been Prescribed BRIUMVI® for Multiple Sclerosis?

You may be eligible to participate in a research study following adults with relapsing forms of multiple sclerosis (RMS) who have been prescribed BRIUMVI® (ublituximab-xiiy).

The study will help researchers learn more about patients' experiences with BRIUMVI® as part of their routine medical care.



Could I Qualify?

You may be eligible if you:

- ✓ Are 18 years of age or older
- ✓ Have been diagnosed with relapsing multiple sclerosis (RMS)
- ✓ Have been prescribed BRIUMVI® but have not yet received your first infusion



What Would Participation Involve?

This is an observational study, which means participating does not change your treatment or require additional study visits, tests or procedures.

Researchers collect information from your routine medical care, including scheduled BRIUMVI® infusions and regular physician visits.

Information collected may include:

- MS relapses
- MRI and laboratory results
- Infusion-related reactions
- Routine physical and cognitive assessments
- Treatment satisfaction and experience

Participants may be followed for up to 192 weeks, or approximately 4 years, with little to no additional study-related contact.



Why Participate?

By participating, you can help researchers better understand the long-term experience of people receiving BRIUMVI® in everyday clinical care and contribute to future MS research.

There is no cost to participate and compensation may be provided. BRIUMVI® is not provided as part of the study.

Interested in Learning More?

Contact our research team to learn more about participation:



404-351-0205 ext 156



fmorehead@atlneuroinstitute.org

ani

atlanta
neuroscience
institute

NOW ENROLLING

Currently Taking Ocrevus[®], BRIUMVI[®] or Kesimpta[®] for

Multiple Sclerosis?

You may be eligible to participate in a clinical research study for adults with Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS).

The study is evaluating an under-the-skin (subcutaneous) form of Ocrevus[®] (ocrelizumab), including treatment experience, safety and patient satisfaction.



Could I Qualify?

You may be eligible if you:

- ✓ Are between 18 and 65 years of age
- ✓ Have been diagnosed with Relapsing MS (RMS) or Primary Progressive MS (PPMS)
- ✓ Are currently receiving Ocrevus[®], BRIUMVI[®] or Kesimpta[®]



What Would Participation Involve?

Participants will transition from their current anti-CD20 treatment to subcutaneous Ocrevus[®] as part of the study.

The medication is administered by a clinical research nurse in the research infusion center as an under-the-skin injection that typically takes less than 15 minutes.

Over approximately 12 months, participation includes four planned study visits and may include:

- Physical exams and health assessments
- MRI scans and laboratory testing
- Questionnaires about your treatment experience

All study-related visits, procedures, testing, MRIs and study medication are provided at no cost to participants.



What Are Researchers Studying?

Researchers want to better understand:

- Treatment experience and satisfaction
- Safety and tolerability
- MS-related health outcomes
- Quality of life and patient-reported experiences



Why Participate?

By participating, you can contribute to research evaluating another way of receiving Ocrevus[®] and help researchers better understand the treatment experiences of people living with MS.

Compensation is available for study visits and MRI-related study procedures.

Interested in Learning More?

Contact our research team to learn more about participation:



404-351-0205 ext 156



fmorehead@atlneuroinstitute.org

ani

atlanta
neuroscience
institute

NOW ENROLLING

Living With Relapsing MS and Recently Started BRIUMVI®?

You may be eligible to participate in a research study from Atlanta Neuroscience Institute (ANI) and Georgia State University (GSU).

The study is following people with relapsing multiple sclerosis (MS) who are being treated with BRIUMVI® (ublituximab) to better understand changes in walking, balance, mobility and physical function over time.



Could I Qualify?

You may be eligible if you:

-  Have relapsing multiple sclerosis (MS)
-  Are being treated with BRIUMVI®
-  Have not yet received your second BRIUMVI® dose
-  Speak and understand English



Will the Study Change My MS Treatment?

This study observes people who are already being treated with BRIUMVI®. The medication is not provided as part of the study, and treatment decisions remain between you and your healthcare provider.



Why Participate?

By participating, you can help researchers better understand how mobility and physical function change over time in people with MS who are treated with BRIUMVI® and contribute to future MS research.

Compensation may be available for study participation.



What Would Participation Involve?

Participants will complete four study visits over approximately one year, with study activities taking place at both Atlanta Neuroscience Institute and Georgia State University.

Visits may include:

- Walking and balance assessments
- Mobility and physical function testing
- A bone density assessment (DXA scan)
- Other study evaluations

Visits at ANI and GSU take approximately two hours or less. Rest breaks are available during testing as needed.

The DXA scan and other study-related procedures are provided at no cost to participants.

Interested in Learning More?

Contact our research team to learn more about participation:



404-351-0205 ext 156



fmorehead@atlneuroinstitute.org